Wino115 wrote: This is one of our better "comps" as discussed by others here. Here's their announcement today about an interim dose trial release. Notice, they give over a weeks advanced notice of a data release, combine it with the investigator, remind investors what the FDA rules were, dates, patients, next steps. A good model for THTX too follow. Don't do that 8am surprise all in one release. Get an investigator or Rothenburg on and make it a full call with Q&A. Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer Dec 27, 2021 Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1 dose-expansion cohort at Company event scheduled for Wednesday, Jan. 5, 2022 at 5 pm ET, or 2 pm PT SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 Sutro Biopharma, Inc. (Sutro), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced today that it will provide interim data from the Companys ongoing dose-expansion cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolR) targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer, at a Company hosted KOL virtual event. The event and Q&A session will be available by webcast, to be held on Wednesday, Jan. 5, 2022, at 5 pm ET, or 2 pm PT. The Phase 1 dose-expansion cohort includes advanced ovarian cancer patients with progressive disease, who had previously received up to three lines of therapy, and is open to patients who have not been selected on the basis of FolR-expression. The study had a target enrollment of 40 patients, with the first patient dosed in January 2021 and completed enrollment with 44 patients in November 2021. The data will be presented by Sutro management and Dr. R. Wendel Naumann, Principal Investigator in the STRO-002-GM1 studies. Dr. Naumann is a professor and Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at the Levine Cancer Institute, Atrium Health in Charlotte, North Carolina. Dr. Naumann is also a member of Sutros Clinical Advisory Board.